No­var­tis pays $70M up­front to li­cense Chi­nese biotech’s an­ti­tu­mor drug

No­var­tis is spend­ing $70 mil­lion up­front on a small mol­e­cule an­ti­tu­mor drug from the Chi­nese biotech Cheng­du Baiyu.

The Swiss drug­mak­er will get an ex­clu­sive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER